Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
93.76
+1.53 (1.66%)
Mar 3, 2026, 3:41 PM EST - Market open
Guardant Health Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for Guardant Health stock have an average target of 117.8, with a low estimate of 55 and a high estimate of 180. The average target predicts an increase of 25.64% from the current stock price of 93.76.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock from 20 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 7 |
| Buy | 14 | 15 | 15 | 13 | 12 | 12 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 23 | 23 | 21 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $120 → $130 | Buy | Maintains | $120 → $130 | +38.65% | Feb 24, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $170 → $180 | Buy | Maintains | $170 → $180 | +91.98% | Feb 20, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $135 → $150 | Strong Buy | Maintains | $135 → $150 | +59.98% | Feb 20, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $125 → $135 | Strong Buy | Maintains | $125 → $135 | +43.98% | Feb 20, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $120 → $130 | Buy | Maintains | $120 → $130 | +38.65% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
1.27B
from 982.02M
Increased by 29.73%
Revenue Next Year
1.63B
from 1.27B
Increased by 27.71%
EPS This Year
-2.51
from -3.32
EPS Next Year
-1.59
from -2.51
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.4B | 2.0B | |||
| Avg | 1.3B | 1.6B | |||
| Low | 1.1B | 1.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 41.6% | 55.3% | |||
| Avg | 29.7% | 27.7% | |||
| Low | 16.0% | 6.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.73 | -0.77 | |||
| Avg | -2.51 | -1.59 | |||
| Low | -3.33 | -2.57 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.